the respective countries were elicited from local experts and clinical guidelines in addition to 1L> 2L BEV sequences obtained from the ML18147 trial. Results: When 1L> 2L BEV replaces sequences which include 1L anti-EGFR regimens, it results in an average potential cost reduction of ARS-42,796
To profile the use of an operator in immunobiological supplemental health Fortaleza -Brazil, to identify the most prescribed therapeutic regimens and costs. METHODS: Cross-sectional study in two hospitals accredited service provider, from March to November/2012. Data were recorded by medical expertise in computerized management system (Sabius ® ) performed after the medical consultation. Later, these were entered in Microsoft Excell 2007 and analyzed by pharmacists auditors. The cost was calculated from the value contained in Brasíndice Unit 765, using the Consumer Price Max. The doses used for rheumatoid arthritis Etanercept 50 mg, 40 mg Adalimumab, abatacept 750 mg, 300 mg infliximab, 560 mg Tocilizimabe, Rituximab 1g and Golimumab 50 mg based on a 70 kg adult. RESULTS: We analyzed 64 patients with a mean weight 67 kg, of which 70.31% (n = 45) were women aged 30-59 years whose most frequent indications were rheumatoid arthritis (n = 33, 51.56%) and ankylosing spondylitis (n = 19; 29.69%). The most immunobiological commonly prescribed were Infliximab (n = 36; 56.25%), Tocilizimabe (n = 11, 17.19%), abatacept, and Rituximab (n = 8; 12, 50%) and golimumab (n = 1, 1.56%). It was observed that 67% (n = 43) patients were naïve immunobiological and 33% (n = 21) initiated with anti-TNF, whereas 61.9% (n = 13) moved into one another with immunobiological mechanism of action and 38.1% (n = 8) continued with an anti-TNF, changing only the drug. The average cost of treatment/dose first line
Objectives: European registries of Rheumatoid Arthritis (RA) patients treated by biological agents suggest that 70-80% are maintained in first line at 1 year despite potential insufficient efficacy. Post hoc analyses of certolizumab pegol (CZP) studies indicate that a 3 month clinical response had a high predictive value of the 1 year outcome. The objective was to examine the efficiency of a strategy consisting of early switching from CZP to a second line TNF inhibitor in case of insufficient clinical response at 3 months (3M) in the French setting versus current clinical practices. MethOds: A decision-tree model was built to estimate the clinical outcomes (ACR50 cumulated time) and the direct costs of different cohorts of RA patients over a 2 year period. ACR50 was considered as an RA satisfying clinical outcome. The "3M tight control" strategy consisted of stopping CZP at 3 months in patients not achieving the ACR50 criterion and switching them to other biologics. Three reference cohorts treated with first line CZP, etanercept or adalimumab, respectively, according to current clinical practices were considered as comparators (reference). All TNF inhibitors were assumed to have equal efficacy in first line. Costs were estimated at 2013 French public prices. Results: The proportion of patients achieving ACR50 after a 2 year follow-up was 58% in all reference cohorts and 75% in the "3M tight control" CZP strategy cohort. The costs per patient-year in ACR50 were € 19,326 with the "3M tight control" strategy cohort and € 23,588, € 26,774 and € 30,285 for the CZP, etanercept and adalimumab reference cohorts, respectively. The strategy "3M tight control" had an incremental cost-effectiveness ratio of € 5,605/patient-year in ACR50 versus CZP reference, and was dominant versus etanercept or adalimumab reference. cOnclusiOns: A 3-month tight control management of RA patients with CZP as first line treatment is cost-effective compared to alternatives.
A7152012 el consumo de ATB aumentó un 32% (de 7.4 a 9.8 DHD). El patrón de consumo total estuvo dado principalmente por las penicilinas de amplio espectro (53%, 61.1 DHD), siendo la amoxicilina el ATB más usado (44%, 50,5 DHD). ConClusiones: Las medidas regulatorias permitieron disminuir el consumo y los costos/DDD de ATB en Chile. Sin embargo, el aumento progresivo observado indica la necesidad de revisar la calidad en la utilización de los ATB y el cumplimiento de la regulación vigente.
A541and events attributed to OIC including the negative impact on job-related activities. Methods: A prospective longitudinal study conducted in the United States (US), Canada (CN), UK (UK), and Germany (GE) of patients with OIC who have been on opioid therapy for at least four weeks was conducted. OIC related medical history and health care resource use was collected from participants self report. The number of hours missed from work and the extent to which the work productivity and regular daily activities were affected was collected using the WPAI-SHP. Results: A total of 489 eligible participants (US: 238; CN: 38;, GE: 115; UK: 98). Back pain (77%) and joint pain (52%) were the most common pain diagnosis with an average duration of chronic pain and opioid medication use of 10 and 6 years respectively. 27% of participants were currently employed. 18% of participants used at least one prescription laxative; 70% reported using at least one over-the-counter (OTC) laxative with the most common being stimulant laxatives (20%), osmotic laxatives (15%) and stool softeners (7%). 63% of participants reported discussing OIC with a health care provider, 3.0% reported a visit to the emergency room and 2.0% reported being admitted to a hospital because of their OIC during a 6-month time period. 9% of employed participants reported missing an average of 4.6 hours per week because of problems associated with constipation and 32% reported impairment while working due to constipation. ConClusions: The cumulative impact of OTC use, physician office visits and the negative impact on work-related activities for OIC may be substantial.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.